Shots:
- Voro Therapeutics has entered into a research collaboration with Daiichi Sankyo via its Daiichi Sankyo Research Institute, San Diego to develop tumor-activated biologics using the PrimeBody platform
- The collaboration will focus on generating masked ADCs designed for tumor-selective activation, using proprietary masking domains & protease-cleavable linkers to improve therapeutic index
- Voro will design & characterize ADC candidates against a selected oncology target, leveraging its PrimeBody tech & prior success, incl. its CD47 blocker program, to expand targeting of previously challenging tumor antigens
Ref: Businesswire | Image: Voro Therapeutics &Daiichi Sankyo | Press Release
Related News: GAIA and Daiichi Sankyo Europe Partner to Launch Lipodia for Hypercholesterolemia in Europe
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
